Diabetes is a chronic condition reported to affect 366 million people globally in 2011 and estimated to rise to 552 million by 2030 worldwide, i.e. one in 10 adults. In the UK alone, the prevalence is 4.5% and approximately 5 million people are projected to be affected in 2025. Of the entire population of people with diabetes, Type 2 Diabetes Mellitus (T2DM) constitutes more than 90%. In the United Kingdom Prospective Diabetes Study (UKPDS), 50% of the people with T2DM presented with micro and/or macrovascular complications at the time of diagnosis. It is well established that people with T2DM also have 4 to 5 times greater risk of cardiovascular complications compared to the general population, accounting for 80% of mortality. Thus, the burden of diabetes and its associated complications on health care services are enormous. Prescribing medications for the complications associated with diabetes alone costs 3 to 4 times more than the cost of medications for managing diabetes in the National Health Service (NHS). Thus, therapies that simultaneously target glycaemic control and diabetic complications particularly cardiovascular disease (CVD) independent of their glucose lowering effect are desirable.